Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 513

Results For "CHI"

5475 News Found

Luke Coutinho launches e-commerce venture YouCareLifestyle
Healthcare | October 19, 2021

Luke Coutinho launches e-commerce venture YouCareLifestyle

The platform will be a curated marketplace for sustainable-driven products by small-medium entrepreneurs and will encourage an autonomous marketplace


WHO to take call on Covaxin's EUL on October 26th
News | October 18, 2021

WHO to take call on Covaxin's EUL on October 26th

The WHO chief scientist Soumya Swaminathan tweeted on Oct. 17


U.S. FDA approves Roche’s Tecentriq as adjuvant treatment for small cell lung cancer
Drug Approval | October 18, 2021

U.S. FDA approves Roche’s Tecentriq as adjuvant treatment for small cell lung cancer

Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting


U.S. FDA advisory committee recommends J&J booster dose
Biotech | October 18, 2021

U.S. FDA advisory committee recommends J&J booster dose

U.S. FDA to decide whether to authorize a booster dose in the coming days


Ipsen enters exclusive worldwide tie-up with Accent for its pre-clinical R&D oncology pipeline
Biotech | October 18, 2021

Ipsen enters exclusive worldwide tie-up with Accent for its pre-clinical R&D oncology pipeline

Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor programme


Resilience and Harvard announce five-year R&D alliance
News | October 18, 2021

Resilience and Harvard announce five-year R&D alliance

First anticipated spinout from the alliance, Circle Therapeutics, to develop novel muscle stem cell therapies for a variety of skeletal muscle disorders


GPT Healthcare to go public to fund expansion
Hospitals | October 18, 2021

GPT Healthcare to go public to fund expansion

The company operates four mid-sized hospitals with a total bed capacity of 556 in eastern India


Exelixis in-licenses second anti-cancer compound from Aurigene
Biotech | October 15, 2021

Exelixis in-licenses second anti-cancer compound from Aurigene

U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma


AUM Biosciences closes US $ 27 million `Series A’ funding round
Startup | October 15, 2021

AUM Biosciences closes US $ 27 million `Series A’ funding round

Everlife leads the series A round, and SPRIM Global Investments participates in the financing syndicate


Hospitals to accelerate digital investments: Frost & Sullivan
Digitisation | October 14, 2021

Hospitals to accelerate digital investments: Frost & Sullivan

The survey revealed that improving customer experience (CX) and operational efficiencies are top priorities, which healthcare organizations aim to attain by deploying digital health solutions